Phase III trial of Prophage, a HSPPC-96 Vaccine (Vitespen) for newly diagnosed Glioblastoma Multiforme

Trial Profile

Phase III trial of Prophage, a HSPPC-96 Vaccine (Vitespen) for newly diagnosed Glioblastoma Multiforme

Planning
Phase of Trial: Phase III

Latest Information Update: 21 Jan 2016

At a glance

  • Drugs Vitespen (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jan 2016 Planned initiation date changed from 1 Dec 2015 to 1 Jul 2016, as per Agenus media release.
    • 16 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top